Reich, N
According to analyst commentary, an Eli Lilly NDA filing could come in Q4 2026 at the earliest
As the worlds largest and most influential conference in the field of diabetes and metabolic diseases, the event brought together leading pharmaceutical companies and research institutions to showcase the latest clinical progress in innovative metabolic therapies
Most GLP-1a weight loss and type diabetes medications require a prior authorization (PA) from the insurance provider: FDA-approved weight loss medications: Contrave, Saxenda (liraglutide), Wegovy (semaglutide) Zepbound (tirzepatide) FDA-approved Diabetes medications: Rybelsis, Victoza (liraglutide), Ozempic (semaglutide), or Mounjaro (tirzepatide) If your insurance company says that they cover FDA-approved diabetes medications, it suggests coverage for patients with type 2 diabetes
The most common side effects are typically gastrointestinal, such as nausea, a feeling of fullness, constipation, or decreased appetite
4 The Oral Pivot : They are already planning for the oral GLP-1 revolution
